Paclitaxel

Paclitaxel Reactions 1704, p289 - 2 Jun 2018 Neutropenia complicated by engraftment syndrome and shock: case report A 71-year-old woman developed neutropenia complicated by engraftment syndrome and shock following treatment with paclitaxel [nabPTX] for breast cancer [route, dosage and time to reaction onset not stated]. The woman, who was diagnosed with left breast cancer, underwent surgery. After the surgery, she received adjuvant chemotherapy with epirubicin and cyclophosphamide, which was followed by treatment with paclitaxel and trastuzumab therapy. She was hospitalised due to severe neutropenia with neutrophil count of 0 /mm . After admission her condition stabilised. However, after three days, she went into a shock and was transferred to the ICU. The woman was treated with cytokine adsorption therapy, after which her condition improved rapidly. After five days, she was extubated and was shifted to the general ward. Eventually, she was discharged without any problems in the next few months. As a significant improvement was observed in her condition after cytokine adsorption therapy, engraftment syndrome was considered. Author comment: "The patient was hospitalized due to severe neutropenia(neutrophils 0/mm3) from [paclitaxel]". "In this case, FN or cardiovascular diseases was ruled out, and engraftment syndrome was considered given that cytokine adsorption therapy significantly improved the patient’s condition." Yoshikawa K, et al. [A Case of Shock Due to nabPTX Administration Successfully Treated with Cytokine Adsorption Therapy]. Gan to Kagaku Ryoho 44: 1358-1360, No. 12, Nov 2017 [Japanese; summarised from an English abstract] - Japan 803322725 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Paclitaxel

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/paclitaxel-Z63R57sLyc
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46932-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p289 - 2 Jun 2018 Neutropenia complicated by engraftment syndrome and shock: case report A 71-year-old woman developed neutropenia complicated by engraftment syndrome and shock following treatment with paclitaxel [nabPTX] for breast cancer [route, dosage and time to reaction onset not stated]. The woman, who was diagnosed with left breast cancer, underwent surgery. After the surgery, she received adjuvant chemotherapy with epirubicin and cyclophosphamide, which was followed by treatment with paclitaxel and trastuzumab therapy. She was hospitalised due to severe neutropenia with neutrophil count of 0 /mm . After admission her condition stabilised. However, after three days, she went into a shock and was transferred to the ICU. The woman was treated with cytokine adsorption therapy, after which her condition improved rapidly. After five days, she was extubated and was shifted to the general ward. Eventually, she was discharged without any problems in the next few months. As a significant improvement was observed in her condition after cytokine adsorption therapy, engraftment syndrome was considered. Author comment: "The patient was hospitalized due to severe neutropenia(neutrophils 0/mm3) from [paclitaxel]". "In this case, FN or cardiovascular diseases was ruled out, and engraftment syndrome was considered given that cytokine adsorption therapy significantly improved the patient’s condition." Yoshikawa K, et al. [A Case of Shock Due to nabPTX Administration Successfully Treated with Cytokine Adsorption Therapy]. Gan to Kagaku Ryoho 44: 1358-1360, No. 12, Nov 2017 [Japanese; summarised from an English abstract] - Japan 803322725 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off